SCHEMBL6718995

SCHEMBL6718995

Cc1cccc(C)c1NC(=O)C(CC(C)C)NC(=S)Nc1ccc(OC(C)N(C)C)cc1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.45
KMT2A Q03164 8/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
ALDH1A1 P00352 10/20 0.43
MAPT P10636 8/20 0.43
NPSR1 Q6W5P4 6/20 0.43
TP53 P04637 2/20 0.42
HTT P42858 3/20 0.42
ANPEP P15144 1/20 0.42
LMNA P02545 3/20 0.41
NPY1R P25929 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
HPGD P15428 1/20 0.40
POLB P06746 1/20 0.40
OPRK1 P41145 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6714162 0.90 MEN1 (0.56) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6714168 0.90 MEN1 (0.56) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6713989 0.89 KMT2A (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL8346261 0.89 KMT2A (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL8345944 0.88 MEN1 (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6718999 0.88 MEN1 (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6716241 0.75 SMN1; SMN2 (0.55) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6716681 0.74 SMN1; SMN2 (0.55) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6715692 0.74 MEN1 (0.55) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL8345950 0.74 ANPEP (0.46) MEN1KMT2ASMN1; SMN2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 MEN1 2933/4885KMT2A 2020/4885SMN1; SMN2 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.